TS and dPCR data for these mutations across four serial plasma samples showed a decline of the initial TP53 mutation associated with treatment response of the dominant CLL clone, followed by emergence of the new TP53 and SF3B1 mutations ∼2 months before the clinical diagnosis of RS (Fig. 2i and Supplementary Fig. 8). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.